Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Nutr Cancer ; 68(8): 1309-1319, 2016.
Article in English | MEDLINE | ID: mdl-27646578

ABSTRACT

Animal and human studies suggest fish oil and green tea may have protective effect on prostate cancer. Fatty acid synthase (FAS) has been hypothesized to be linked to chemoprotective effects of both compounds. This study evaluated the independent and joint effects of fish oil (FO) and green tea supplement (epigallocatechin-3-gallate, EGCG) on FAS and Ki-67 levels in prostate tissue. Through a double-blinded, randomized controlled trial with 2 × 2 factorial design, 89 men scheduled for repeat prostate biopsy following an initial negative prostate biopsy were randomized into either FO alone (1.9 g DHA + EPA/day), EGCG alone (600 mg/day), a combination of FO and EGCG, or placebo. We used linear mixed-effects models to test the differences of prostate tissue FAS and Ki-67 by immunohistochemistry between pre- and post-intervention within each group, as well as between treatment groups. Results did not show significant difference among treatment groups in pre-to-post-intervention changes of FAS (P = 0.69) or Ki-67 (P = 0.26). Comparing placebo group with any of the treatment groups, we did not find significant difference in FAS or Ki-67 changes (all P > 0.05). Results indicate FO or EGCG supplementation for a short duration may not be sufficient to produce biologically meaningful changes in FAS or Ki-67 levels in prostate tissue.


Subject(s)
Catechin/analogs & derivatives , Fatty Acid Synthase, Type I/metabolism , Fatty Acids, Omega-3/pharmacology , Fish Oils/pharmacology , Prostate/enzymology , Aged , Biopsy , Catechin/blood , Catechin/pharmacology , Dietary Supplements , Fatty Acids/blood , Humans , Male , Middle Aged , Prostate/drug effects
3.
Mayo Clin Proc ; 88(2): 129-38, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23312369

ABSTRACT

OBJECTIVE: To identify patients who could safely avoid unnecessary radiation and instrumentation after the detection of microscopic hematuria. PATIENTS AND METHODS: We conducted a prospective cohort study of patients who were referred to urologists and underwent a full evaluation for asymptomatic microscopic hematuria during a 2-year period in an integrated care organization in 3 regions along the West Coast of the United States. A test cohort and validation cohort of patients with hematuria evaluations between January 9, 2009, and August 15, 2011, were identified. Patients were followed passively through their electronic health records for a diagnosis of urothelial or renal cancer. The degree of microscopic hematuria, history of gross hematuria, smoking history, age, race, imaging findings, and cystoscopy findings were evaluated as risk factors for malignant tumors. RESULTS: The test cohort consisted of 2630 patients, of whom 55 (2.1%) had a neoplasm detected and 50 (1.9%) had a pathologically confirmed urinary tract cancer. Age of 50 years or older and a recent diagnosis of gross hematuria were the strongest predictors of cancer. Male sex was also predictive of cancer, whereas smoking history and 25 or more red blood cells per high-power field on a recent urinalysis were not statistically significant. A Hematuria Risk Index developed from these factors had an area under the receiver operating characteristic curve of 0.809. In the validation cohort of 1784 patients, the Hematuria Risk Index performed comparably (area under the curve = 0.829). Overall, 32% of the population was identified as low risk and 0.2% had a cancer detected; 14% of the population was identified as high risk, of whom 11.1% had a cancer found. CONCLUSION: These results suggest that a considerable proportion of patients could avoid extensive evaluations with the use of the Hematuria Risk Index.


Subject(s)
Hematuria/diagnosis , Hematuria/epidemiology , Urologic Neoplasms/diagnosis , Urologic Neoplasms/epidemiology , Age Distribution , Aged , Aged, 80 and over , Asymptomatic Diseases/epidemiology , California/epidemiology , Causality , Cohort Studies , Comorbidity , Early Diagnosis , Female , Humans , Male , Middle Aged , Northwestern United States/epidemiology , Predictive Value of Tests , Prospective Studies , ROC Curve , Risk Factors , Sex Distribution , Sex Factors , United States , Unnecessary Procedures , Validation Studies as Topic
4.
Cancer ; 116(7): 1699-708, 2010 Apr 01.
Article in English | MEDLINE | ID: mdl-20143429

ABSTRACT

BACKGROUND: : A study was conducted to determine the 5-year recurrence-free survival in patients with high-risk prostate cancer after neoadjuvant combination chemotherapy followed by surgery. Secondary endpoints included safety, pathologic effects of chemotherapy, and predictors of disease recurrence. METHODS: : Fifty-seven patients were enrolled in a phase 1/2 study of weekly docetaxel 35 mg/m(2) and escalating mitoxantrone to 4 mg/m(2) before prostatectomy. Patients were treated with 16 weeks of chemotherapy administered weekly on a 3 of every 4 week schedule. A tissue microarray, constructed from the prostatectomy specimens, served to facilitate the exploratory evaluation of biomarkers. The primary endpoint was recurrence-free survival. Disease recurrence was defined as a confirmed serum prostate-specific antigen (PSA) >0.4 ng/mL. RESULTS: : Of the 57 patients, 54 received 4 cycles of docetaxel and mitoxantrone before radical prostatectomy. Grade 4 toxicities were limited to leukopenia, neutropenia, and hyperglycemia. Serum testosterone levels remained stable after chemotherapy. Negative surgical margins were attained in 67% of cases. Lymph node involvement was detected in 18.5% of cases. With a median follow-up of 63 months, 27 of 57 (47.4%) patients recurred. The Kaplan-Meier recurrence-free survival at 2 years was 65.5% (95% confidence interval [CI], 53.0%-78.0%) and was 49.8% at 5 years (95% CI, 35.5%-64.1%). Pretreatment serum PSA, lymph node involvement, and postchemotherapy tissue vascular endothelial growth factor expression were independent predictors of early recurrence. CONCLUSIONS: : Preoperative chemotherapy with docetaxel and mitoxantrone is feasible. Approximately half of the high-risk patients remain free of disease recurrence at 5 years, and clinical and molecular predictors of early recurrence were identified. Cancer 2010. (c) 2010 American Cancer Society.


Subject(s)
Adenocarcinoma/drug therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Mitoxantrone/administration & dosage , Prostatic Neoplasms/drug therapy , Taxoids/administration & dosage , Adenocarcinoma/pathology , Adenocarcinoma/surgery , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Chemotherapy, Adjuvant , Combined Modality Therapy , Docetaxel , Humans , Male , Middle Aged , Neoadjuvant Therapy , Prostate-Specific Antigen/blood , Prostatectomy , Prostatic Neoplasms/pathology , Prostatic Neoplasms/surgery , Recurrence , Risk , Testosterone/blood
5.
Environ Microbiol ; 8(10): 1775-82, 2006 Oct.
Article in English | MEDLINE | ID: mdl-16958758

ABSTRACT

Enumeration of microbial cells without culturing is an essential technique for microbial ecology and water quality evaluation. Here we show that bulk fluorescence using the SYBR Gold DNA stain can be used to rapidly quantify microbial cells per millilitre in fresh, marine and estuarine waters. The bulk fluorescence method is comparable to estimating cell concentrations in cultures using optical density; however, this enhanced method enables the user to estimate microbial numbers at lower concentration (> 10(5) cells ml(-1)) found in environmental samples. The technique worked in both single-cell and 96-well plate fluorescent spectrophotometers. Differences of approximately 10(5) cells per millilitre were discernible and the precision of the bulk fluorescence was higher than direct counting by epifluorescent microscopy. Treatment with DNase I increased sensitivity by lowering background noise attributed to free DNA. This technique is simple, rapid, inexpensive and adaptable for automatically estimating microbial numbers in water samples.


Subject(s)
Fluorescent Dyes/chemistry , Fluorometry/methods , Organic Chemicals/chemistry , Vibrio parahaemolyticus/isolation & purification , Water Microbiology , California , Deoxyribonuclease I/metabolism , Fresh Water/microbiology , Microscopy, Fluorescence , Reproducibility of Results , Seawater/microbiology
7.
MedGenMed ; 7(2): 8, 2005 Jun 30.
Article in English | MEDLINE | ID: mdl-16369387

ABSTRACT

We report the first case of glossal necrotizing myositis by group A beta-hemolytic Streptococcus in an 8-year-old girl on chronic nonsteroidal anti-inflammatory drugs, immunomodulators, and steroids for juvenile rheumatoid arthritis. Treatment included partial glossectomy and parenteral antibiotics. After a critical course, full recovery ensued. The subject of necrotizing myositis is reviewed.


Subject(s)
Myositis/diagnosis , Myositis/therapy , Streptococcal Infections/diagnosis , Streptococcal Infections/therapy , Streptococcus pyogenes/isolation & purification , Anti-Bacterial Agents/therapeutic use , Anti-Inflammatory Agents/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Child , Epiglottitis , Female , Glossectomy , Humans , Myositis/microbiology , Necrosis/diagnosis , Necrosis/therapy , Practice Guidelines as Topic , Practice Patterns, Physicians' , Streptococcal Infections/microbiology
SELECTION OF CITATIONS
SEARCH DETAIL
...